Targeted B-cell agents, such as anti-B cell activating factor (BAFF) Belimumab (47) and Ianalumab (48), anti-CD20 Rituximab (47, 49), can relieve some systemic symptoms and remain the most promising therapeutic drugs for pSS (44). This evidence concerns the gene TNFSF13B and peeling skin syndrome.